Hamilton Lane Advisors LLC raised its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 50.8% during the fourth quarter, HoldingsChannel.com reports. The firm owned 23,241 shares of the medical equipment provider’s stock after buying an additional 7,827 shares during the quarter. ABIOMED comprises 2.3% of Hamilton Lane Advisors LLC’s holdings, making the stock its 13th largest position. Hamilton Lane Advisors LLC’s holdings in ABIOMED were worth $4,356,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Koch Industries Inc. grew its stake in shares of ABIOMED by 40,431.3% during the second quarter. Koch Industries Inc. now owns 799,277 shares of the medical equipment provider’s stock valued at $794,000 after buying an additional 797,305 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of ABIOMED by 102.0% during the third quarter. Janus Henderson Group PLC now owns 1,076,829 shares of the medical equipment provider’s stock valued at $181,553,000 after buying an additional 543,793 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of ABIOMED by 2,219.4% during the third quarter. Wells Fargo & Company MN now owns 364,427 shares of the medical equipment provider’s stock valued at $61,443,000 after buying an additional 348,715 shares during the last quarter. American Century Companies Inc. grew its stake in shares of ABIOMED by 99.8% during the third quarter. American Century Companies Inc. now owns 484,142 shares of the medical equipment provider’s stock valued at $81,626,000 after buying an additional 241,868 shares during the last quarter. Finally, FMR LLC bought a new position in shares of ABIOMED during the second quarter valued at approximately $32,609,000. Institutional investors and hedge funds own 90.75% of the company’s stock.

In related news, VP Michael G. Howley sold 10,000 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $178.64, for a total value of $1,786,400.00. Following the transaction, the vice president now owns 56,757 shares of the company’s stock, valued at $10,139,070.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Dorothy E. Puhy sold 6,364 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $179.08, for a total value of $1,139,665.12. Following the completion of the transaction, the director now directly owns 39,532 shares in the company, valued at approximately $7,079,390.56. The disclosure for this sale can be found here. 7.00% of the stock is owned by corporate insiders.

A number of research analysts have recently commented on the company. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 target price on the stock in a research note on Tuesday, November 7th. BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Jefferies Group upped their target price on ABIOMED from $175.00 to $208.00 and gave the company a “buy” rating in a research note on Friday, September 29th. Piper Jaffray Companies upped their target price on ABIOMED to $200.00 and gave the company an “overweight” rating in a research note on Thursday, October 26th. Finally, BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a research note on Sunday, October 29th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. ABIOMED has a consensus rating of “Buy” and an average target price of $199.67.

Shares of ABIOMED, Inc. (NASDAQ ABMD) traded up $6.04 during trading hours on Wednesday, reaching $224.13. The company had a trading volume of 535,188 shares, compared to its average volume of 265,664. ABIOMED, Inc. has a 52 week low of $103.53 and a 52 week high of $225.24. The company has a market capitalization of $9,910.00, a PE ratio of 110.41, a P/E/G ratio of 2.84 and a beta of 0.15. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.20 and a current ratio of 5.84.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.16. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The company had revenue of $132.80 million for the quarter, compared to analysts’ expectations of $131.18 million. During the same quarter in the prior year, the firm earned $0.20 earnings per share. ABIOMED’s revenue was up 28.9% compared to the same quarter last year. sell-side analysts anticipate that ABIOMED, Inc. will post 2.41 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Hamilton Lane Advisors LLC Buys 7,827 Shares of ABIOMED, Inc. (ABMD)” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/01/17/hamilton-lane-advisors-llc-buys-7827-shares-of-abiomed-inc-abmd.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.